•
Mar 31, 2020

Globus Medical Q1 2020 Earnings Report

Globus Medical's Q1 2020 financial results were announced, revealing a sales increase and resilience amidst the COVID-19 pandemic.

Key Takeaways

Globus Medical reported a 4.2% increase in worldwide sales, reaching $190.6 million in Q1 2020. Despite the COVID-19 pandemic's estimated $20 million negative impact on sales, the company maintained profitability with a net income of $25.9 million and a non-GAAP adjusted EBITDA of 26.5% of sales. The company launched three new spine products during the quarter and ended the quarter with $657 million in cash, cash equivalents and marketable securities.

Worldwide sales increased by 4.2% to $190.6 million.

Net income for the first quarter was $25.9 million.

Diluted EPS was $0.25, and non-GAAP diluted EPS was $0.29.

Non-GAAP adjusted EBITDA was 26.5% of sales.

Total Revenue
$191M
Previous year: $183M
+4.2%
EPS
$0.29
Previous year: $0.36
-19.4%
Adjusted EBITDA as % of sales
26.5%
Previous year: 31.1%
-14.8%
Gross Profit
$142M
Previous year: $141M
+0.4%
Cash and Equivalents
$167M
Previous year: $130M
+28.3%
Free Cash Flow
$20M
Previous year: $11M
+80.8%
Total Assets
$1.48B
Previous year: $1.34B
+10.7%

Globus Medical

Globus Medical

Globus Medical Revenue by Segment

Globus Medical Revenue by Geographic Location

Forward Guidance

Globus Medical withdrew its full year 2020 guidance due to the uncertainties related to the COVID-19 pandemic.

Revenue & Expenses

Visualization of income flow from segment revenue to net income